About ERIX
EiRx Therapeutics is a specialist provider of pre-clinical therapeutics to the pharmaceutical industry. Our unique scientific expertise and knowledge in the field of Apoptosis provide a sound base to discover and develop new medicines that will safely and selectively repair this natural process in disease. The potential benefits from these new medicines are enormous, since as many as 70% of all human disease have some defect in the control of Apoptosis.
Apoptosis - the biological process that determines whether cells in our bodies live or die...
http://www.eirx.com/index.html

Purchased some of these on the strength of the PROGRESS UPDATE looks promising.
http://moneyam.uk-wire.com/cgi-bin/articles/200603200701130254A.html

ERX interview with John Pool
http://www.wallstreetreporter.com/interview.php?id=18589&player=real
Latest News
CANCER COLLABORATION WITH BIOMERIEUX SA
http://moneyam.uk-wire.com/cgi-bin/articles/200607120700230534G.html
Biomerieux Web Site
http://www.biomerieux.com/servlet/srt/bio/portail/home
ABOUT ERX Focus Of The Month
http://www.billamag.net/focus-document-text.asp?FocusTextID=1
ERX pdf filehttp://www.eirx.com/eirx_heading_images/Yokohama2005.pdf
19/09/2006 A 50% reduction in breast tumour volume size seen with Eirx lead molecule in animal studies
http://moneyam.uk-wire.com/cgi-bin/articles/200609190700171175J.html

Past and present collaborative partners include:

* bioMieux SA
* Almac Diagnostics Ltd
* Merck & Co, Ltd
* Biofocus plc
* MGI Pharmaceuticals, Inc
* OSI Pharmaceuticals, Inc
* Sareum plc
* Regen Therapeutics plc
* SR Pharma plc

PH put a link to the information and explain why it is relevant and people can choose to look or not. Keep it simple and short!

That's a good idea ph, a link please as it is I don't read most off your long posts as I am well past middle age and so I can't spare the time.

Mr Turbot
PH Has got his own thread but he just likes to annoy us on here he gets a kick out of it, he also treats fellow investors with contempt and yes he will dump when he is ready and then deramp the answer is to squash him if you have had enough.

guys I post it as it is relevant, its a good idea to DYOR, I just give a bit of source for you to use as reference. if ya going to be lazy, why on earth do you trade

Driver, there is one important thing you have missed off your header

who are the major shareholders and how many shares do they have.

I think you will find the ex director is selling off his shares now he is retired

PH
Re "missed off your header"

I can't see it on your thread.

exactly noone has put the info up..

how about you do it

an awful lot of takeovers happening this week...

someone is certainly eating up our stock

potatohead

Are they lightly to confirm any milestone payments on there results day 11 Nov Approx?

Lots of 500000 going through @ 0.0032 showing as sell but they must be buys.

Marcel
They are buys just checked Barclays 500000 to buy at .32

why do you think share price has dropped?

marcel1970 because the hype has

700202
The hype may have dropped but the volume hasnt a few months ago you would have been lucky to have seen a couple of trades for the whole day, happy to hold at these levels till we get more news. If you believe in ERX top up on the dips.

DRIVER I believe and am holding 5 mil and will top up , but get fed up with idiots putting old or unconnected news hype on the site
could be massive news for cancer sufferers, without the crap

what crap, its all relevant, its all about cancer.. so your statement is contradictive 700202

I think some of it PH is that its old and they have seen it all before !!

actually none of it is old, it comes straight from google news

ya plonker

Some is new yes, but some is old and some has jack sh*t to do with ERX + all links are at the top of this thread for all to read IF THEY WANT TO,AND WHAT plonker keeps saying news tomorrow a week ago !! :)))) IF Ramping was an Olympic sport you would get GOLD for sure !!

MGI PHARMA Recognized for Innovation & Growth
Nov 2 2006, 3:01 PM EST
BIOWIRE


MGI PHARMA, INC. (NASDAQ:MOGN), a biopharmaceutical company focused in oncology and acute care, today announced it has received two awards for product innovation and revenue growth. The Company was named a 2006 Minnesota Tekne Award winner in the Established Biotechnology category, and was ranked 212th on the Deloitte Technology Fast 500 list for North America.

"These two awards are testament to the hard work and dedication of our talented associates," stated Lonnie Moulder, President and CEO of MGI PHARMA. "I'd like to thank them for the critical roles they've played in enabling MGI PHARMA to bring to market innovative products for patients."

The Minnesota Tekne Awards honors companies, innovations and individuals that make a positive impact on Minnesota's technology-based economy. The Minnesota High Tech Association (MHTA) and Minnesota Technology, Inc. (MTI), in partnership with LifeScience Alley join together annually to celebrate and recognize those companies and individuals who have made superior contributions to the development, commercialization, and management of technology in the State of Minnesota.

The 2006 Deloitte Technology Fast 500 is a ranking of the 500 fastest growing technology, media, telecommunications and life sciences companies in North America. Rankings are based on percentage revenue growth over five years (2001-2005). MGI PHARMA's total revenue grew from $33 million to $279 million in this time frame.

To qualify for the Fast 500, entrants must own proprietary intellectual property or proprietary technology that contributes to a significant portion of the company's operating revenues or devotes a significant portion of revenues to research and development of technology. Base-year operating revenues must be at least $50,000 USD and current-year operating revenues must be at least $5 million USD. Companies must also be in business for five years and be headquartered within North America.